https://t.co/b0KrNGOs8Y our group’s first publication in autoimmune diseases. Congratulations to Kinman and all the coauthors! We are Applying from what we learned from cancer to treat autoimmune diseases. #BMErocks#learnfromcancer#T1DM#LCCC#immunotherapy.
We are so proud of now Dr. Tilden Hagan @TildenHagan for passing his thesis defense this morning! He will now go back to medical school to get one more doctorate! Congratulations Tilden! @UNC_Lineberger @UNCNCSUBME @BMEGrads@UNC_SOM@UNCmdphd @UNCRadOnc
Our latest publication is online! Kinman did a stellar job! Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy https://t.co/jeDjpeGfqH
Just over a week until Andrew Wang MD, Assoc. Prof., Dept. of Radiation Oncology, UNC and Cofounder of Capio Biosciences will present our CapioCyte™ Technology on January 22nd at PMWC 2020. https://t.co/Uq7gyVSFLq @capiobio@PMWCintl#biomarkers#oncology#CirculatingTumorCells
This is a huge step for our #bladdercancer patients! Enfortumab vedotin, novel ADC, with 42% ORR in refractory mUC, ~70% disease control rate. Thank you @FDAOncology! https://t.co/fnrKprIFaH
Feeling excited. Just heard that all the hurdles have been cleared and Archimmune therapeutics (a new startup company) will soon become a reality. Can’t wait to get the work started
A somber day as we mourn the loss of Senator Kay Hagan, our very own Tilden Hagan’s mother. Senator Kay Hagan was an amazing public servant who gave her all to North Carolina. Our hearts are with Tilden and the rest of the Hagan family
@PepPamies@natBME Agree. I think we need to stop obsessing over dose to tumor which we may or may not be able to improve. Rather, the differential dose to tumor vs normal tissue as well as clinical relevance will decide our success. Also, the BIND story is much more complicated...
https://t.co/mSvKCzU3rc - an ASCO run resource for cancer patients. Had the privilege of editing the #kidneycancer section this year. Thank you to @montypal@neerajaiims@PGrivasMDPhD for including me!
@natBME Also, you should clarify NCI did not halt the CCNE program. It supported 3 cycles, which is more than any other initiatives. Nano field is becoming mature so it doesn’t need any more special programs. We were all expecting it.